Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

<p><strong>Background</strong> This study aimed to evaluate AZD2816, a variant-updated COVID-19 vaccine expressing the full-length SARS-CoV-2 beta (B.1.351) variant spike protein that is otherwise similar to AZD1222 (ChAdOx1 nCoV-19), and AZD1222 as third-dose boosters.</p>...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Ramasamy, MN, Kelly, EJ, Seegobin, S, Dargan, PI, Payne, R, Libri, V, Adam, M, Aley, PK, Martinez-Alier, N, Church, A, Jepson, B, Khan, M, Matthews, S, Townsend, GT, Vekemans, J, Bibi, S, Swanson, PA, Lambe, T, Pangalos, MN, Villafana, T, Pollard, AJ, Green, JA
Další autoři:	AZD2816 Study Group
Médium:	Journal article
Jazyk:	English
Vydáno:	Elsevier 2023

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Podobné jednotky